March 23, 2018 / 6:02 AM / 5 months ago

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

March 23 (Reuters) - Ipsen Sa:

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below